India · Delayed Price · Currency is INR CORONA Remedies Statistics
Total Valuation
CORONA Remedies has a market cap or net worth of INR 98.72 billion. The enterprise value is 98.81 billion.
| Market Cap | 98.72B |
| Enterprise Value | 98.81B |
Important Dates
The last earnings date was Monday, February 2, 2026.
| Earnings Date | Feb 2, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CORONA Remedies has 61.16 million shares outstanding. The number of shares has decreased by -0.03% in one year.
| Current Share Class | 61.16M |
| Shares Outstanding | 61.16M |
| Shares Change (YoY) | -0.03% |
| Shares Change (QoQ) | -0.09% |
| Owned by Insiders (%) | 69.00% |
| Owned by Institutions (%) | 6.30% |
| Float | 6.17M |
Valuation Ratios
The trailing PE ratio is 57.61 and the forward PE ratio is 44.59. CORONA Remedies's PEG ratio is 1.62.
| PE Ratio | 57.61 |
| Forward PE | 44.59 |
| PS Ratio | 7.35 |
| PB Ratio | 14.97 |
| P/TBV Ratio | 20.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 1.62 |
Enterprise Valuation
| EV / Earnings | 57.67 |
| EV / Sales | 7.35 |
| EV / EBITDA | 33.85 |
| EV / EBIT | 39.69 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.21 |
| Debt / FCF | n/a |
| Interest Coverage | 32.95 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 27.81% |
| Return on Capital Employed (ROCE) | n/a |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 2.99M |
| Profits Per Employee | 380,764 |
| Employee Count | 4,500 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CORONA Remedies has paid 579.49 million in taxes.
| Income Tax | 579.49M |
| Effective Tax Rate | 25.27% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 66.41 |
| Average Volume (20 Days) | 60,438 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CORONA Remedies had revenue of INR 13.44 billion and earned 1.71 billion in profits. Earnings per share was 28.02.
| Revenue | 13.44B |
| Gross Profit | 10.86B |
| Operating Income | 2.49B |
| Pretax Income | 2.29B |
| Net Income | 1.71B |
| EBITDA | 2.88B |
| EBIT | 2.49B |
| Earnings Per Share (EPS) | 28.02 |
Balance Sheet
The company has 539.60 million in cash and 627.10 million in debt, with a net cash position of -87.50 million or -1.43 per share.
| Cash & Cash Equivalents | 539.60M |
| Total Debt | 627.10M |
| Net Cash | -87.50M |
| Net Cash Per Share | -1.43 |
| Equity (Book Value) | 6.60B |
| Book Value Per Share | 107.80 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 80.79%, with operating and profit margins of 18.51% and 12.75%.
| Gross Margin | 80.79% |
| Operating Margin | 18.51% |
| Pretax Margin | 17.06% |
| Profit Margin | 12.75% |
| EBITDA Margin | 21.45% |
| EBIT Margin | 18.51% |
| FCF Margin | n/a |
Dividends & Yields
CORONA Remedies does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.03% |
| Shareholder Yield | 0.03% |
| Earnings Yield | 1.74% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |